5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Section C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will acquire treatment until sickness progression or maybe the participants are unable to tolerate the study drugs.and after that boost H3K27Ac at this region. Chromatin hyperacetylation could raise the acces